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Summary To increase the accessibility of drug-antibody complexes to tumours and to decrease non-specific
binding via Fc receptors N-acetyl-melphalan (N-AcMEL) was conjugated to F(ab')2 fragments. These
fragments were synthesised by pepsin degradation of IgG MoAb. Up to 20 molecules of N-AcMEL could be
successfully coupled to each F(ab')2 fragment (compared with 25 molecules/intact IgG) with retention of both
drug and antibody activity. The N-AcMEL-F(ab')2 conjugates demonstrated specific cytotoxicity in vitro
however despite the absence of non specific Fc receptor binding and greater permeability when using F(ab')2
fragments, the N-AcMEL-F(ab')2 and N-AcMEL-IgG conjugates had similar anti-tumour activity in vii'o.
Conjugates made with whole IgG and F(ab'), were equally effective in eradicating subcutaneous solid
tumours in mice when injected intravenously. The lower immunogenicity of F(ab')2 fragments compared with
whole lgG and the similar cytotoxicity of their conjugates, suggests that the F(ab'), conjugate has greater
clinical utility.
The selective delivery of antineoplastic agents to tumours is
a concept which has led to the search for methods of drug
targeting. One approach with chemotherapeutic drugs
involves chemical modification of existing compounds to
form prodrugs which although pharmacologically inert can
be converted to active agents at tumour sites (Stella et al.,
1980). Generally, this approach is limited, however, we have
recently incorporated this 'prodrug' concept into an
alternative approach which uses monoclonal antibodies
(MoAbs) to specifically target drugs to tumours (Smyth et
al., 1986a). By covalently conjugating an inactive N-acetyl
derivative of melphalan (N-AcMel) ('prodrug') to MoAbs
involved in endocytotic pathways (Smyth et al., 1986b),
tumour specific conjugates were produced which were
cytotoxic following internalisation and lysosomal
degradation within the target tumour cell. These N-AcMEL-
MoAb conjugates displayed in vitro and in vivho specificity
and cytotoxicity (Smyth et at., 1986a) however, in an
attempt to improve results in vivo we now report on thecoupling
of F(ab'), fragments to N-AcMEL. The use of F(ab'),
fragments should have several advantages; firstly the non-
specific binding to non-tumour cells via Fc receptors would
be avoided; secondly the Fc portion is the most immuno-
genic portion of the MoAb so that if the use of murine
MoAbs is contemplated for therapy, then the less immuno-
genic F(ab')2 preparation could be desirable. Finally the
removal of the Fc portion of the MoAb decreases its
molecular size by approx. 30%, which has been considered
to permit conjugates to more efficiently permeate the
physiological barriers and avoid cellular barriers (reticulo-
endothelial system) when passing from the circulation to a
tumour (Poznansky et al., 1984). Subsequently we
investigated and compared the in vitro and in vivo efficacy of
F(ab')2 conjugates with conjugates of N-AcMEL and intact
IgG MoAb.
Materials and methods
Tumi?our cells
E3, a clonal variant of the murine thymoma ITT(1)75NS
(Smyth et al., 1986c); and the murine lymphoma EL4
(Horowitz Ct al., 1968) were maintained in vitro in
Dulbecco's Modified Eagles medium (DME) supplemented
with 10% heat inactivated newborn calf serum (Flow
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Laboratories, Sydney, Australia), 2mm glutamine (Common-
wealth Serum Laboratories, (CSL), Melbourne, Australia),
100pg streptomycin (Glaxo, Melbourne, Australia) and
100 IU ml - penicillin (CSL). For in vivo experiments E3 was
maintained by serial passage in the ascites form in
(C57BL/6xBALB/c)Fl (CBFJ) mice; cells from the ascites
fluid were washed and centrifuged (400g x 5min) twice in
DME and PBS (pH 7.3) resuspended in PBS, and injected
into CBF1 mice.
Mice
CBFI mice were produced in the Department of Pathology,
University of Melbourne.
Monoclonal antibodty
The anti-Ly-2.1 MoAb (IgGl) (Hogarth et at., 1982) was
isolated from ascitic fluid by precipitation with 40%
ammonium sulphate, and the IgG fraction was adsorbed
onto Protein A Sepharose (Pharmacia, Piscataway, NJ),
washed extensively with PBS (pH 7.3) and eluted with 0.2M
glycine/HC1 (pH 2.8). Following neutralisation, the MoAb
was dialysed against PBS, aliquoted and stored at -70 C.
The antibody activity was determined by rosetting with
sheep anti-mouse immunoglobulin (SAMG) (Parish et al.,
1978).
Preparation of F(ab')2 by pepsin degradation1
The optimal conditions of degradation adopted for
preparation of F(ab')2 fragments of the anti-Ly-2.1 MoAb
were 0.1 M citrate, pH3.8, at 37 C for 6-8h using IgG
concentrations of 1 to 2mgml1 and pepsin concentrations
of 25pgml- (Parham, 1983). Intact IgG was removed using
Protein A-Sepharose (Pharmacia) and each preparation was
calculated for yield (>80%) and characterized by
polyacrylamide gel electrophoresis under reducing and non-
reducing conditions.
Prepar-ation ofN-AcMEL-IgG and N-AcMEL-F(ab')2
conjugates
An N-acetyl derivative of MEL was prepared and
conjugated to whole IgG and F(ab')2 as described (Smyth et
al., 1986a). Briefly, MEL was acetylated using acetic
anhydride and an active ester of this N-AcMEL derivative
was then coupled to the amino groups of the MoAb.
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Antiodly (aCtilviti'
A rosetting assay (Parish et al., 1978) has previously
demonstrated the antibody activity of N-AcMEL-IgG
conjugates (Smyth et at., 1986a). The antibody activity of N-
AcMEL-F(ab')2 conjugates was compared with whole IgGI
and F(ab')2 fragments in a competitive binding assay using
radiolabelled '251-IgG. In this assay double dilutions were
performed using 25pi antibody, 25jul F(ab')2 conjugates or
25,il IgG conjugate in a 96 well round bottom plate and to
these 25,il of '251-anti-Ly-2.1 was added, 50pl of E3 target
cells (1.5 x 106 ml-1) were then added and incubated for
30min before washing ( x 3) in PBS and cutting the plate
and counting individual samples in a gamma counter. It
should be noted that control wells did not include 25SI of
cold' antibody or conjugate and results were calculated as
the percentage reduction in I' :Dl-anti-Ly-2.1 binding o0
control samples.
Drug activiti
Two assays measuring the incorporation of [3H] thymidine
into tumour cells were performed to assess the drug activity
of F(ab')2 conjugates, these differing in the time the
conjugate was in contact with the cells. (a) 24h assay: lOOul
of cells (1-5 x 106 ml- ') were added to a 96 well flat bottom
microtitre plate and incubated for I h at 37 C. Free drug
(prepared by dissolution in 0.5 M sodium bicarbonate) and N-
AcMEL conjugates F(ab'), and IgG were filtered through
a 0.22 tum millipore tilter to ensure sterility and dilutions
were performed in sterile PBS; 50 ul of free drug or N-
AcMEL conjugates were added to cells using duplicate
wells/sample. Control wells received 50pi of medium or PBS
and the cells were cultured at 37 C in a 7% CO2 atmosphere
for 24h, or (b) 30min assay: 200upl of cells (1-5 x 106 ml-1)
were collected in sterile plastic centrifuge tubes, resuspended
in sterile drug or F(ab')2 conjugate and mixed for 30min at
37 C. The cells were centrifuged (400gx5min) and then
resuspended in growth medium; 1001,l of cells were then
seeded into a microtitre plate using duplicate wells/sample
and incubated for 16-24h. After the incubation period in
both assays, 50ul of medium containing 1 lCi of [3H]-
thymidine (specific activity- 5Cimmol-1; Amersham) was
added and the plates incubated for 2-4h; cells were then
harvested; dried for 0min at 80 C and samples counted on
a scintillation counter. Incorporation of [3H]-thymidine was
expressed as a percentage inhibition in incorporation of
controls. Standard error for any given point was generated
by duplicate determinations and did not exceed 5% for any
given experimental point.
In vivo experiments
Tumiiour growtth Tumour cells were injected s.c. into the
abdominal wall and were allowed to develop into palpable
tumours before commencing treatment. Mice were then
subjected to a series of i.v. treatments and the size of the
tumours measured daily with a caliper square measuring
along the perpendicular axes of the tumours; the data were
recorded as the mean tumour size (product of two
diameters+s.e.). Experimental groups of 8-10 mice, all of
the same sex and age were used in each experiment.
Results
These studies were designed to demonstrate that N-AcMEL
could be covalently coupled to F(ab')2 fragments of MoAbs
whilst maintaining drug and antibody activity in vitro and to
compare these conjugates with N-AcMEL covalently bound
to IgG MoAb in solid tumour models.
Coupling of N-AcMEL to F(ab')2
The anti-Ly-2.1 F(ab')2 was reacted with different amounts
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Figure 1 Coupling of N-AcMEL to anti-Ly-2.1 F(ab'),
(0.5mg). Molecules of N-AcMEL incorporated per moleculc
anti-Ly-2.1 F(ab'), (a) and protein recovery (0) is shown as a
function of the number of n mol of N-AcMEL in the reaction
mixture (abscissa).
of N-AcMEL active ester to produce conjugates which
varied in the amount of drug coupled. It was found that the
addition of 230nmol of N-AcMEL active ester to 5 nmole of
F(ab')2 led to an incorporation of 6 molecules of N-AcMEL
per molecule F(ab')2 with a 85% recovery of protein (Figure
1). By contrast the addition of twice as much N-AcMEL
active ester (460 nmol) led to the incorporation of 25
molecules of N-AcMEL with recovery of 55% of the
protein. The conditions for successful coupling had therefore
been established and F(ab')2 conjugates that were tested
further in vitro and in vivo had between 10-20 molecules of
N-AcMEL incorporated per molecule of F(ab')2. It was clear
that N-AcMEL could be covalently bound to F(ab')2
fragments with some loss of protein; however the drug and
antibody activity of the conjugates required measurement.
Antibody activit of NN-AcMEL-F(ab')2 conjugates
The titres of antibody before and after degradation and
conjugation to N-AcMEL were measured by a competitive
radiolabel binding assay (Figure 2) [i.e. the dilution of cold
antibody at which 35% (half the maximum binding
observed) of the 1251-anti-Ly-2.1 binding to E3 target cells
was reduced]. F(ab')2 conjugates containing 20 molecules of
N-AcMEL had an antibody titre of 1:32, the unconjugated
F(ab')2 titre was 1:32 and the anti-Ly-2.1 titre was 1:100.
Thus there is clearly some loss of antibody activity upon
pepsin degradation to F(ab')2 fragments; however, no further
measurable loss occurred upon conjugation of up to 20 N-
AeMEL molecules. When N-AcMEL incorporation ratios
exceeded 20 molecules a significant loss in antibody activity
was observed (data not shown).
C0totoxicitv in vitro
The cytotoxicity of the anti-Ly-2. I F(ab')2 conjugate was
tested on Ly-2± E3 cells and compared with that of free N-
AcMEL and N-AcMEL covalently bound to anti-Ly-2.1. It
was clear that the cytotoxic activity of the F(ab')2 conjugate
was considerably greater than free N-AcMEL and slightly
greater than N-AcMEL-IgG conjugate (Figure 3). For
example, the 50% inhibition in [3H]-thymidine incorporation
occurred at a N-AcMEL concentration of 7.5 x 10-6M for
the F(ab')2 conjugate compared to 4.0 x 10-4 M for free N-
AcMEL and 9.0 x 10-6M for N-AcMEL-IgG. Thus F(ab'),
conjugate and IgG conjugate were 40-50 times more
cytotoxic than free N-AcMEL.
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Figure 2 Antibody titre measured as the percentage reduction in
2iI-F(ab'), binding v.s. antibody dilution of F(Lb'), conjugate
on ITT(1)75NS E3 target cells. Several dilutions were performed
uponi a t).8 mg ml solutioni of cither Canti-Ly-2.1 (A). anti-Ly-
2.1 F(ab'), (U) or F(ab'), conjugate (0) 20mol N-
AcMELmoIl colnjugatc.
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Figure 3 The inhibitory effect of free N-AcMEL (M). N-
AcMEL covalently bound to anti-Ly-2.1 MoAb, 20mol N-
AcMELmol-' conjugate (0) or N-AcMEL covalently bound to
F(ab'), MoAb, 20mol N-AcMELmol-' conjugate (0) on E3
cells in a 24 h assay (see text).
Specific (COYtOX.iCitl'
It was necessary to show that the inhibitory activity of N-
AcMEL F(ab'), conjugates was specific for target cells
reactive with the MoAb as previously described for N-
AcMEL-IgG conjugates (Smyth et a!l., 1986ca). Using the
30 min assay one F(ab')2 conjugate and two cell lines were
used. The F(ab')2 conjugate was demonstrated to bind the
Ly-2+ E3 cell line and exert its cytotoxicity on these cells
after 30min exposure (Figure 4), 50% inhibition in [3H]-
thymidine incorporation occurred at a N-AcMEL concen-
Concentration N-AcMEL (M)
Figure 4 The inhibitory effect of free N-AcMEL (*) or N-
AcMEL-F(ab')1 conjugate, 20mol N-AcMEL mol-' conjugate
(0) on antibody reactive cells (E3) and free N-AcMEL (D) or
conjugate (0) on antibody non-reactive cells (EL4) in the 30min
assay.
tration of 1.5 x 10M compared with 1.5x10 M for free
N-AcMEL. By contrast EL4 (Ly-2-) which was 10 times
more sensitive to free N-AcMEL than E3 was relatively
resistant to the cytotoxic effect of the F(ab'), (Ly-2+)
conjugate over the molar concentration range tested.
Tumour gro1t/t
Groups of 10 CBFI mice injected s.c. with 3.0 x l(6 E3
tumour cells developed a solid tumour 4 days after tumour
inoculation and were injected i.v. with one ot the following
treatments: (i) PBS; (ii) free N-AcMEL; (iii) F(ab')2; (iv) a
covalent N-AcMEL-IgG conjugate; and (v) a covalent N-
AcMEL-F(ab')2 conjugate. Groups received 15pg of N-
AcMEL and/or 150plg of IgG or F(ab')2 on days 4 and 5.
There was inhibition of tumour growth in mice which
received either N-AcMEL conjugate, compared to those
receiving PBS, N-AcMEL or antibody alone (Figure 5). By
day 6 the conjugate groups had smaller tumours than either
the N-AcMEL or F(ab')2 treated mice and by day 11 the
mean tumour size of N-AcMEL-IgG treated mice was 50%
that of PBS treated mice. Even more effective was the
F(ab'), conjugate treatment which had reduced the mean
tumour size of that group to 60% of the mean size of the
PBS treated group. When monitoring the individual tumour
growth curves of the F(ab')2 conjugate treated mice two
complete regressions were observed and a further 4/10 of the
mice demonstrated a reduction in tumour size during the
course of the treatment (data not shown). By day 11
however those tumours that had regressed began to
redevelop and grew at half the rate of PBS treated tumours.
In order to assess the limitation of N-AcMEL-F(ab')2 and
N-AcMEL-IgG treatment using smaller tumour loads and
earlier treatment, another experiment was designed in which
groups of 10 CBF1 mice were injected s.c. with 2.0 x 106 E3
tumour cells. These developed a solid tumour 4 days after
tumour inoculation. Mice were injected i.v. on days 3, 5 and
6 after tumour inoculation with either PBS, anti-Ly-2. 1,
MEL, N-AcMEL covalently bound to anti-transferrin MoAb
(anti-TFR) (Smyth et al., 1986a) or N-AcMEL-anti-Ly-2.1
F(ab'), conjugate. The amount of N-AcMEL or MEL
administered was 8,g on day 3, 15pg on day 5 and 7pg on
day 6 (i.e. total 30pg N-AcMEL). As previously noted, those
mice receiving N-AcMEL and anti-Ly-2.1 in their treatments
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Figure 5 Growth of the thymoma ITT(1)75NS E3 in CBF1
mice injected s.c. with 3 x 106 cells. Groups of 10 mice were given
treatments i.v. denoted (M); PBS (El), free N-AcMEL (-), N-
AcMEL-anti-Ly-2. 1 conjugate (0), N-AcMEL-F(ab')2 conjugate
(0) and anti-Ly-2.1 F(ab')2 (A). Errors bars represent+ s.e. of
the mean tumour size.
had smaller tumours than those receiving PBS, MEL or
antibody alone (Figure 6) just seven days after tumour
inoculation and by day 11 the mean tumour size of F(ab')2
conjugate treated mice was 15% that of PBS treated mice
and 20% that of N-AcMEL-anti-TFR treated mice. The
individual tumour growth curves of F(ab')2 conjugate treated
mice revealed that 9/10 of the mice demonstrated a reduction
in tumour size during the treatment period (days 5-6), 5 of
these tumours completely regressing and not redeveloping
(Figure 7). At the termination of F(ab')2 conjugate treatment
the remaining 4 tumours began to increase in size, growing
at variable rates all slower than the mean growth rate of
PBS treated mice. It is also clear that one of the mice only
demonstrated a minor response to the F(ab')2 conjugate. In
an additional group of mice treated identically with N-
AcMEL-IgG (anti-Ly-2.1) conjugate 4/10 of the tumours
were completely eradicated (data not shown).
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Figure 6 Growth of the thymoma ITT(1)75NS E3 in CBF,
mice injected s.c. with 2 x 106 cells. Groups of 10 mice were given
the following treatments i.v. denoted (t); PBS (O1), free MEL (*),
N-AcMEL-F(ab')2 conjugate (0), N-AcMEL-anti-TFR con-
jugate (O) and anti-Ly-2.1 (-). Error bars represent+s.e. of the
mean tumour size.
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To reduce the non-specific toxicity of MEL, a less cytotoxic
N-AcMEL derivative was synthesised and coupled to
MoAbs (Smyth et al., 1986a). This N-AcMEL-IgG conjugate
was demonstrated to enter cells via the MoAb not the
phenylalanine amino acid transport system and therefore was
only cytotoxic to cells which bound the MoAb. In addition
N-AcMEL-IgG conjugates more effectively eradicated
tumours in vivo than free MEL, N-AcMEL or antibody
alone, being most efficacious when administered i.v. (Smyth
et al., 1986a). In this study we have attempted to further
increase the specificity and cytotoxicity of N-AcMEL-IgG
conjugates by cleaving the Fc portion of the MoAb and
coupling the derived F(ab')2 fragment to N-AcMEL. Using
the same conjugation procedure as for N-AcMEL-IgG
conjugates (Smyth et al., 1986a), the N-AcMEL active ester
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Figure 7 Individual tumour growth curves of CBFl mice
injected s.c. with 2 x 106 ITT(l)75NS E3 tumour cells and treated
i.v. (T) on days 3, 5 and 6 with N-AcMEL-F(ab')2 conjugate.
The broken line represents the mean tumour size of PBS treated
mice.
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was successfully coupled to F(ab')2 fragments and conjugates
with up to 20 molecules of N-AcMEL bound per molecule
F(ab'), were produced (Figure 1). In addition to retaining its
F(ab'), activity (Figure 2), the F(ab')2 conjugate was shown
to retain the cytotoxic effect of N-AcMEL, increasing the
anti-tumour activity of bound N-AcMEL to 50 times that of
an equimolar amount of free N-AcMEL (Figure 3). The
F(ab')2 conjugate also exhibited specificity to target cells in
cytotoxicity assays performed in vitro (Figure 4). The F(ab')2
binding activity of the conjugate clearly resulted in the
conjugates selective cytotoxicity, as the F(ab')2 conjugate
displayed cytotoxicity only to Ly-2+ E3 cells being more
cytotoxic than N-AcMEL alone.
These in vitro studies were performed to ascertain whether
the F(ab')2 fragments could be covalently coupled to N-
AcMEL with retention of the conjugate's specificity and
cytotoxicity. The conjugation of F(ab')2 fragments of anti-
Ly-2.1 to N-AcMEL has been demonstrated to be
comparable to the conjugation of whole anti-Ly-2.1 and N-
AcMEL, except that fewer N-AcMEL molecules can be
bound to F(ab')2 whilst retaining antibody activity, protein
solubility and recovery. Not surprisingly therefore, the
F(ab')2 conjugate was as cytotoxic as the intact IgG
conjugate in vitro.
Once the cytotoxic activity of the F(ab')2 conjugate had
been established in vitro, the in vivo efficacy of the F(ab'),
conjugate was investigated using established solid tumour
models. In the first s.c. tumour growth experiment, therapy
did not commence until palpable lumps were established and
of the i.v. treatments administered the F(ab')2 conjugate was
the most effective tumour inhibitor (Figure 5). Its effect was
only marginally superior to N-AcMEL-IgG treatment and of
all the F(ab')2 conjugate treated mice that demonstrated a
reduction in tumour size (6/10) only two mice had tumours
that completely regressed, these too redeveloping 6 days after
the completion of treatment. In order to assess the limitation
of conjugate therapy considering the promising anti-tumour
activity of i.v. conjugate treatment in individual mice, we
injected CBF1 mice s.c. with 2.0 x 106 cells and began i.v.
treatments one day prior to solid tumour development.
Although in this and the initial tumour growth experiment,
conjugate treated mice received 30,ug of N-AcMEL, a
greater reduction in tumour size was achieved with earlier
treatment. Individual tumour growth curves demonstrated
that 9/10 of the tumours reduced in size during the course of
treatment (Figure 7) and five of these tumours regressed and
did not reappear (>200 days), a result which represents our
first successful i.v. cure of s.c. implanted ITT(1)75NS E3
tumours using the i.v. route of administration. Earlier i.v.
treatment of mice with 30,ug of N-AcMEL-lgG was almost
as effective as F(ab')2 conjugate treatment and thus by
varying tumour cell number and treatment schedule in two
tumour growth experiments we have been unable to
demonstrate a major difference in the in vivo efficacy of the
N-AcMEL-IgG conjugate and the F(ab')2 conjugate. An
important feature of F(ab')2 fragments is their inability to
bind Fc receptors on macrophages and hepatocytes which
should therefore limit conjugate accumulation in the liver
and the reticuloendothelial system and on account of their
smaller size, F(ab')2 conjugates should also be capable of
penetrating the capillary network of the tumour. In contrast
however, the shorter half life (faster clearance) and generally
lower affinity of F(ab')2 fragments may result in a lower
concentration of F(ab')2 conjugate in the tumour than is
possible with intact IgG conjugate (Wahl ct al., 1983). In
this case it remains unclear, which of these properties of
MoAbs is the most important when delivering cytotoxic
drugs to tumours.
Additionally, it is evident that kinetics of MoAb uptake,
the relationship between tumour size and MoAb binding and
the site of MoAb deposition are valuable criteria in
determining the relative effectiveness of F(ab')2 and intact
MoAb-drug conjugates. Consequently, the possibility of
using F(ab')2 conjugates therapeutically will depend on
giving doses high enough to compensate for their rapid
clearance from the tumour site.
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